
Validea's guru fundamental report rates Amgen (AMGN), a large-cap biotechnology and drugs stock, at 87% using Pim van Vliet's Multi-Factor Investor model. This model, which prioritizes low volatility stocks exhibiting strong momentum and high net payout yields, suggests AMGN holds 'some interest' for investors seeking low-risk outperformance, aligning with van Vliet's research on conservative equities.
According to Validea's fundamental report, Amgen, Inc. (AMGN) scores a relatively high 87% using the Pim van Vliet Multi-Factor Investor model, which targets low volatility stocks with strong momentum and high net payout yields. This score suggests the strategy has 'some interest' in the stock. Delving into the model's specific criteria reveals a mixed assessment: AMGN passes on Market Cap and, crucially for this strategy, on Standard Deviation, indicating it meets the low-volatility requirement. However, it only achieves a 'NEUTRAL' rating for both 'Twelve Minus One Momentum' and 'Net Payout Yield', falling short of the 'strong' and 'high' characteristics the model typically seeks. The most significant contradiction is that despite the favorable 87% score, the stock receives a 'FAIL' on the 'FINAL RANK' metric, creating a notable discrepancy between the overall rating and the final, decisive criterion within the model's framework.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment